Cardiac arrest & resuscitation

Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation (mean arterial pressure (MAP)‐CARE): A protocol for a randomized clinical trial

Acta Anaesthesiol ScandPublished Protocol for a randomised controlled trial

An erratum to this article was published (Acta Anaesthesiol Scand, Mar 2026 ↗)

Study context

Population
Adults with sustained ROSC who are comatose after OHCAplanned sample size
Participants
3,500 adults
Planned comparison
Higher vs lower MAP target after resuscitation
Primary endpoint
Mortality
Follow-up
6 months
Methodological details2 x 2 x 2 factorial (STEPCARE), international, multicentre, parallel-group, investigator-initiated, superiority, Neurological prognostication per ERC and ESICM guidelines by a physician blinded to allocation, Sample size gives 90% power, alpha 0.05, to detect 5.6 absolute risk reduction in 6-month mortality, assuming 60% control mortality, Secondary outcomes: poor functional outcome and patient-reported overall health at 6 months; predefined severe adverse events
  • 2 x 2 x 2 factorial (STEPCARE)
  • International
  • Multicentre
  • Parallel-group
  • Investigator-initiated
  • Superiority
  • Neurological prognostication per ERC and ESICM guidelines by a physician blinded to allocation
  • Sample size gives 90% power, alpha 0.05, to detect 5.6 absolute risk reduction in 6-month mortality, assuming 60% control mortality
  • Secondary outcomes: poor functional outcome and patient-reported overall health at 6 months; predefined severe adverse events

No results yet. This paper sets out the design of a trial; its results are to come.

Original publication

Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation (MAP‐CARE): A protocol for a randomized clinical trial. Acta Anaesthesiol Scand. Published 20 May 2025. doi:10.1111/aas.70040

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.